WO2020195302A1 - 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用 - Google Patents

細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用 Download PDF

Info

Publication number
WO2020195302A1
WO2020195302A1 PCT/JP2020/005760 JP2020005760W WO2020195302A1 WO 2020195302 A1 WO2020195302 A1 WO 2020195302A1 JP 2020005760 W JP2020005760 W JP 2020005760W WO 2020195302 A1 WO2020195302 A1 WO 2020195302A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
group
linker molecule
cell membrane
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/005760
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
慶士 高津
敏裕 鹿倉
優佳 石場
達也 馬渡
博文 前田
寛士 北
北野　光昭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Priority to JP2021508238A priority Critical patent/JP7611815B2/ja
Publication of WO2020195302A1 publication Critical patent/WO2020195302A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof

Definitions

  • the present invention presents a linker molecule for producing a cell-penetrating cyclic peptide, a peptide complex into which the linker molecule has been introduced and a method for producing the same, a peptide library containing the peptide complex, and screening of a functional peptide using the peptide library. Regarding the method.
  • therapeutic agents for specific diseases and molecules having a high affinity for target molecules have been selected from a peptide (polypeptide) library having various amino acid sequences.
  • a ribosome display method using a ribosome display complex containing a peptide chain, an mRNA molecule, and a ribosome is known (for example, a patent). Reference 1).
  • the RD method if they have in vitro translation system and mRNA, only mixing them, in which very good useful which can be produced 10 12 or more peptide library in a few minutes.
  • Techniques for incorporating the active ingredient into the cell include, for example, a method of fusing the amino acid sequences of a cell membrane penetrating peptide containing a large amount of basic amino acids, and a dendrimer which is a dendrimer polymer having a regularly branched structure from the center.
  • the method to be used see, for example, Patent Document 2 and the like are known.
  • a molecule that imparts cell membrane penetrating performance to a peptide having a cyclic structure can be a valuable drug discovery seed, and a peptide library containing such a peptide is a very useful means for the search.
  • RNA is bound to a peptide translated from the RNA by modifying it with a modifying reagent at a specific time. It is known that the adhesive function of ribosomes can be maintained without losing the original function (see, for example, Patent Document 3).
  • Non-Patent Document 1 As a technique for cyclizing a peptide and imparting cell membrane permeability, an example in which these are performed stepwise has been reported (see, for example, Non-Patent Document 1).
  • An object of the present invention is to solve the above-mentioned problems in the past and to achieve the following objects. That is, in the present invention, a linker molecule for producing a cell-penetrating cyclic peptide capable of simultaneously performing cyclization of the peptide and imparting cell membrane permeability to the peptide, a peptide complex into which the linker molecule has been introduced, and production thereof It is an object of the present invention to provide a method, a peptide library containing the peptide complex, and a method for screening a functional peptide using the peptide library.
  • the present inventors unexpectedly synthesize a molecule in which a cell membrane permeability-imparting group and a cyclic group that cyclizes a peptide coexist in the same molecule. It was found that the peptide can be cyclized and cell membrane permeability can be imparted to the peptide at the same time by using this molecule.
  • the present invention is based on the above-mentioned findings of the present inventors, and the means for solving the above-mentioned problems are as follows. That is, ⁇ 1> A linker molecule for producing a cell-penetrating cyclic peptide, which comprises a cell membrane-penetrating cyclic peptide-imparting group and a cyclic group that cyclizes a peptide. ⁇ 2> A peptide complex comprising a peptide and the linker molecule according to ⁇ 1> introduced into the peptide. ⁇ 3> A peptide library comprising the peptide complex according to ⁇ 2> above.
  • ⁇ 4> A method for producing a peptide complex, which comprises the step of introducing the linker molecule according to ⁇ 1> into the peptide.
  • ⁇ 5> A method for screening a functional peptide, which comprises a step of screening a functional peptide using the peptide library according to the above ⁇ 3>.
  • a cell-penetrating cyclic peptide capable of solving the above-mentioned problems in the past, achieving the above-mentioned object, and simultaneously performing cyclization of the peptide and impartation of cell membrane permeability to the peptide. It is possible to provide a linker molecule for production, a peptide complex into which the linker molecule has been introduced and a method for producing the same, a peptide library containing the peptide complex, and a method for screening a functional peptide using the peptide library.
  • FIG. 1 is a diagram showing the results of preparative HPLC of peptide P in Example 2.
  • FIG. 2 is a diagram showing the results of preparative HPLC of the cyclic peptide (peptide complex G3-DCX-P) in Example 2.
  • FIG. 3 is a schematic diagram of the structure of the template DNA used to prepare the ribosome display complex in Example 3.
  • FIG. 4 is a diagram showing the measurement results of MALDI-TOF MS in Example 4.
  • FIG. 5 is a diagram showing the measurement results of MALDI-TOF MS in Example 5.
  • FIG. 6 is a diagram showing the measurement results of MALDI-TOF MS in Example 6.
  • linker molecule for producing cell-penetrating cyclic peptide
  • the linker molecule for producing a cell-penetrating cyclic peptide of the present invention (hereinafter, may be referred to as “linker molecule”) has at least a cell membrane-penetrating cyclic peptide-imparting group and a cyclic group that cyclizes the peptide, and is necessary. It also has other configurations such as linking groups, depending on the situation.
  • the linker molecule can be represented by the following general formula (1).
  • ABC ⁇ ⁇ ⁇ General formula (1) In the general formula (1), "A” represents a cyclic group, “B” represents a linking group or a single bond, and “C” represents a cell membrane permeability-imparting group.
  • the cyclic group contributes to the cyclization of the peptide by reacting with a reactive amino acid residue in the peptide described later.
  • the reactive amino acid residue is an amino acid residue that reacts with the cyclic group, may be an amino acid residue that directly reacts with the cyclic group, or is modified so as to react with the cyclic group. It may be an amino acid residue.
  • the cyclic group is not particularly limited and may be appropriately selected depending on the intended purpose, but an electron-withdrawing group is preferable.
  • the electron-withdrawing group is not particularly limited and may be appropriately selected depending on the intended purpose, but it preferably has a halogen.
  • the type of halogen is not particularly limited and can be appropriately selected according to the purpose.
  • halogens are not particularly limited and may be appropriately selected depending on the purpose, but 2 or more is preferable.
  • the electron-withdrawing group preferably has two or more chlorine atoms, more preferably benzyl chloride, which may have a substituent, and particularly preferably a 3,5-bis (chloromethyl) benzyl group.
  • Cyclization of a peptide by the cyclic group may be carried out by reacting the cyclic group with at least one group selected from the group consisting of a thiol group, an amino group and a hydroxy group contained in the peptide. preferable.
  • the cell membrane permeability-imparting group is a group that imparts cell membrane permeability to the peptide.
  • the cell membrane permeability-imparting group preferably has a basic functional group.
  • the mode of the cell membrane permeability-imparting group is not particularly limited and may be appropriately selected depending on the intended purpose, but a mode having a dendritic structure is preferable.
  • the number of dendritic structural units in the cell membrane permeability-imparting group is not particularly limited and may be appropriately selected depending on the intended purpose, and may be one or two or more.
  • the number of branches per dendritic structural unit is not particularly limited and may be appropriately selected depending on the intended purpose, but 3 or more is preferable.
  • the structure of the branch of the dendritic structure is not particularly limited and may be appropriately selected depending on the intended purpose.
  • the basic functional group is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a guanidino group, an amino group and an imidazole group. Among these, it is preferable to have a guanidino group.
  • the basic functional group may be used alone or in combination of two or more.
  • the number of the basic functional groups is not particularly limited and may be appropriately selected depending on the intended purpose, but 2 or more is preferable.
  • the basic functional group preferably has two or more guanidino groups.
  • the position of the basic functional group in the linker molecule is not particularly limited and may be appropriately selected depending on the intended purpose, but it is preferably located at the end of the branch of the dendritic structure.
  • the cell membrane permeability-imparting group having a dendritic structure include those represented by the following general formula (C).
  • the general formula (C) represents a cell membrane permeability-imparting group having a dendritic structure having three branches, and "Y" in the formula represents a basic functional group.
  • the basic functional group may be formed at the ends of all branches, or may be formed at the ends of some branches.
  • the cell membrane permeability-imparting group may have a plurality of dendritic structures represented by the general formula (C), and in that case, the number of branches may be, for example, 6 or 9.
  • the other constitution of the linker molecule is not particularly limited as long as the effect of the present invention is not impaired, and can be appropriately selected depending on the intended purpose. Examples thereof include a linking group.
  • the linking group is a group that links the cell membrane permeability-imparting group and the cyclic group.
  • the structure of the linking group is not particularly limited and may be appropriately selected depending on the intended purpose.
  • linker molecule examples include compounds represented by the following structural formulas.
  • the linker molecule represented by the following structural formula has a 3,5-bis (chloromethyl) benzyl group as a cyclic group and three guanidino groups at the end of the dendritic structure as a cell membrane permeability-imparting group. This is an example in which the cyclic group and the cell membrane permeability-imparting group are linked via a linking group.
  • the method for producing the linker molecule is not particularly limited and may be appropriately selected depending on the intended purpose.
  • a cell membrane permeability-imparting group precursor forming step and a linking group are added to the cell membrane permeability-imparting group precursor.
  • Examples include a step of forming and a method including. Each of the above steps can be carried out by appropriately selecting a known chemical synthesis technique.
  • the cell membrane permeability-imparting group precursor forming step can be performed by the method described in US Pat. No. 7,862,807 and the like.
  • the method for confirming whether or not the obtained linker molecule has a desired structure is not particularly limited, and a known analysis method can be appropriately selected. For example, mass spectrometry and proton nuclear magnetic resonance spectroscopy can be selected. , Carbon 13 nuclear magnetic resonance spectroscopy, ultraviolet spectroscopy, infrared spectroscopy and other analytical methods.
  • linker molecule of the present invention cyclization of the peptide and impartation of cell membrane permeability to the peptide can be performed in one step, so that these can be easily achieved in a short time.
  • the peptide complex of the present invention comprises at least the peptide and the linker molecule of the present invention introduced into the peptide, and further comprises other configurations as required.
  • the peptide is not particularly limited as long as it is cyclized by introducing the linker molecule, and can be appropriately selected depending on the intended purpose.
  • the amino acid residue (hereinafter, may be referred to as “reactive amino acid residue”) used for introducing the linker molecule is not particularly limited and may be appropriately selected depending on the intended purpose.
  • cysteine Residues, lysine residues, serine residues, threonine residues and the like can be mentioned.
  • the reactive amino acid residue may be used alone or in combination of two or more.
  • the number of the reactive amino acid residues in the peptide is preferably 2 or more in terms of cyclizing the peptide.
  • the upper limit of the number of the reactive amino acid residues in the peptide is not particularly limited and may be appropriately selected depending on the intended purpose. However, as the number of reaction sites increases, the number and position of the linker molecules that bind to the peptide increase. It is preferably 10 or less because it may not be stable and it may be difficult to compare the characteristics of peptides derived from the amino acid sequence. In addition, for example, when the cysteine residue in the peptide is involved in the stabilization of the higher-order structure of the peptide by disulfide bond, the reactive amino acid residue may be separately introduced into the peptide. preferable.
  • the position of the reactive amino acid residue in the peptide is not particularly limited and can be appropriately selected depending on the intended purpose.
  • RNA chain an mRNA molecule, a peptide chain which is a translation thereof (hereinafter, may be referred to as “polypeptide chain”), and a ribosome display complex containing ribosome (hereinafter, referred to as “RD complex”).
  • RD complex a ribosome display complex containing ribosome
  • it is a portion protruding from the exit tunnel (exit tunnel) of the ribosome, and specifically, the position (N) from the second N-terminal to the 30th C-terminal. It is preferable to set it between (including the second position from the terminal and the 30th position from the C terminal) in that the modification reaction by the linker molecule can be less likely to be sterically inhibited by the ribosome.
  • the position from the C-terminal the 50th position from the C-terminal is preferable, and the 100th position is more preferable.
  • the position can be appropriately set according to the chain length of the peptide, and is, for example, the 2nd to 1,000th position from the N-terminal.
  • the 2nd to 100th positions from the N-terminal are preferable, and the 2nd to 50th positions from the N-terminal are more preferable.
  • the method for producing the RD complex is not particularly limited, and a known method can be appropriately selected. Examples thereof include the method described in International Publication No. 2017/213158. It can also be manufactured using a commercially available kit.
  • the amino acid sequence of the peptide is not particularly limited and may be appropriately selected depending on the intended purpose, but one containing a random sequence at a specific position is preferable so as to be useful as a peptide library. From such a random sequence, a useful amino acid sequence can be specified according to a predetermined purpose.
  • the position of the random sequence in the peptide is not particularly limited and may be appropriately selected depending on the intended purpose.
  • the position is not particularly limited. It is preferably between the 2nd position from the N-terminal to the 30th position from the C-terminal (including the 2nd position from the N-terminal and the 30th position from the C-terminal). That is, the reactive amino acid residue is preferably contained in a random sequence. Therefore, the preferred position of the random sequence can be set from the same range as the preferred position of the reactive amino acid residue.
  • the number of the random sequences in the peptide may be one or two or more.
  • the upper limit of the number of the random sequences is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably 10 or less.
  • the number of amino acid residues per random sequence is not particularly limited and may be appropriately selected depending on the intended purpose, and may be, for example, 1 or more and 30 or less. The longer one random sequence and the larger the number of random sequences, the greater the diversity of the peptide library.
  • the peptide may further contain a sequence for purifying a polypeptide chain such as a FLAG® sequence or a polyHis sequence, a sequence selectively cleaved by a protease or the like, a spacer sequence, or the like.
  • a sequence for purifying a polypeptide chain such as a FLAG® sequence or a polyHis sequence, a sequence selectively cleaved by a protease or the like, a spacer sequence, or the like.
  • the number of amino acid residues of the peptide is not particularly limited and may be appropriately selected depending on the intended purpose, and may be, for example, 10 or more and 5,000 or less.
  • the lower limit of the number of amino acid residues of the peptide is preferably 150 or more, more preferably 200 or more.
  • the upper limit of the number of amino acid residues of the peptide is preferably 800 or less, more preferably 600 or less, and particularly preferably 500 or less.
  • the lower limit value and the upper limit value can be appropriately combined and selected.
  • the method for synthesizing the peptide is not particularly limited, and a known method can be appropriately selected.
  • the linker molecule is the above-mentioned linker molecule for producing a cell-penetrating cyclic peptide of the present invention.
  • the linker molecule is introduced into the peptide by reacting the cyclic group in the linker molecule with the reactive amino acid residue in the peptide. During the reaction, the structure of the cyclic group changes.
  • the other constitution of the peptide complex is not particularly limited as long as the effect of the present invention is not impaired, and can be appropriately selected depending on the intended purpose.
  • a luminescent substance such as a fluorescent substance, a dye, a radioactive substance, etc.
  • examples thereof include drugs, toxins, nucleic acids, amino acids, sugars, lipids, and various polymers. These may be used alone or in combination of two or more.
  • the fluorescent substance is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include fluorescent dyes such as fluorescein, rhodamine, coumarin, pyrene and cyanine.
  • the other constitution can be attached to the above-mentioned peptide, for example, directly or via a linking group or the like.
  • the method for producing a peptide complex of the present invention includes at least a linker molecule introduction step of introducing the linker molecule of the present invention into the peptide, and further includes other steps as necessary.
  • the linker molecule introduction step is a step of introducing the linker molecule of the present invention into a peptide (hereinafter, may be referred to as "binding", “inserting”, or “linking”).
  • binding By the linker molecule introduction step, the cyclization of the peptide and the impartation of cell membrane permeability to the peptide can be performed at the same time.
  • the linker molecule introduction step the linker molecule may be introduced into at least one peptide in the reaction product, but it is preferable that the linker molecule is introduced into all the peptides.
  • the peptide is the same as that described in the item ⁇ Peptide> of the above (peptide complex).
  • the peptide may be in the form of a peptide library.
  • the method of introduction is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include a method of reacting the linker molecule with the peptide in the presence of a reducing agent.
  • the reducing agent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include tris (2-carboxyethyl) phosphine hydrochloride.
  • the conditions such as the temperature and time of the reaction are not particularly limited and may be appropriately selected depending on the intended purpose.
  • the method for confirming whether or not the obtained peptide complex has a desired structure is not particularly limited, and a known analysis method can be appropriately selected. For example, mass spectrometry and proton nuclear magnetic resonance spectroscopy can be selected. Analytical methods such as method, carbon-13 nuclear magnetic resonance spectroscopy, ultraviolet spectroscopy, and infrared spectroscopy can be mentioned.
  • the peptide library of the present invention contains at least the peptide complex of the present invention, and further contains other configurations as required.
  • the peptide library may consist only of the peptide complex of the present invention, or may contain a peptide that has not been cyclized.
  • the peptide library can be produced in the same manner as described above (method for producing a peptide complex).
  • the method for screening a functional peptide of the present invention includes at least a step of screening a functional peptide using the peptide library of the present invention, and further includes other steps as necessary.
  • the screening method is not particularly limited as long as the peptide library of the present invention is used, and a known method can be appropriately selected.
  • a desired target substance and the peptide library are mixed, a bound peptide complex (for example, RD complex) is selected, RNA is dissociated from the RD complex, and DNA is prepared from the RNA.
  • a bound peptide complex for example, RD complex
  • RNA is dissociated from the RD complex
  • DNA is prepared from the RNA. Examples thereof include a method of screening for a functional peptide having an affinity for the target substance by repeating the step of transcribing to mRNA and preparing an RD complex library again after amplification.
  • the resin on which the peptide was formed was used as trifluoroacetic acid (TFA) / water / triisopropylsilane / 3,6-dioxa-1,8-octanedithiol (92.5 / 2.5 / 2.5 / 2.5 (92.5 / 2.5 / 2.5 / 2.5).
  • the peptide was excised from the resin by immersing it in (volume ratio)) for 3 hours.
  • the obtained peptide was purified by reverse phase HPLC and freeze-dried to obtain a peptide having the above sequence (hereinafter, may be referred to as "P". See the structural formula below).
  • the identification data of the peptide P by electrospray ionization mass spectrometry (ESI-MS) were as follows. ESI-MS C 72 H 92 N 16 O 22 O 3 Calculated value (M + 2H +) 815.295, measured value 814.67
  • the compound C3 represented by the above structural formula was synthesized by the above reaction formula. Specifically, a methylene chloride solution (15 mL) of compound C1 (500 mg, 0.42 mmol) was cooled to 0 ° C., and compound C2 (manufactured by Tokyo Kasei Kogyo Co., Ltd., product number A2293) (117.5 mg, 0.504 mmol) was cooled. ), 1-Hydroxybenzotriazole (HOBT) (85.1 mg, 0.630 mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC / HCl) (120 mg, 0.630 mmol).
  • HOBT 1-Hydroxybenzotriazole
  • EDC / HCl 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
  • the compound C4 represented by the above structural formula was synthesized by the above reaction formula. Specifically, nitrogen gas bubbling was performed on a solution consisting of compound C3 (533 mg, 0.379 mmol), compound DBXA (188 mg, 0.568 mmol) and THF (40 mL) to create a nitrogen atmosphere. An aqueous solution of copper sulfate (200 mM; 1.89 mL, 0.379 mmol) and an aqueous solution of sodium ascorbate (100 mM; 7.58 mL, 0.758 mmol) were added thereto, and the mixture was stirred at 25 ° C. for 3 hours.
  • the linker molecule G3-DCX for producing a cell-penetrating cyclic peptide represented by the above structural formula was synthesized by the above reaction formula. Specifically, compound C4 (497 mg, 0.286 mmol) and a 4N dioxane hydrochloride solution (30 mL) were mixed and stirred at 25 ° C. for 46 hours. After the reaction, a white solid was precipitated. The supernatant was removed to obtain a crude product of the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide.
  • the peptide complex G3-DCX-P represented by the above structural formula was synthesized by the above reaction formula. Specifically, the peptide P (4.8 mg, 3.0 ⁇ mol) synthesized in Preparation Example 1 was dissolved in 50 mM ammonium bicarbonate buffer (1.0 mL), and tris (2-carboxyethyl) phosphine (TCEP) (TCEP). 0.94 mg (3.3 ⁇ mol) was added, and the mixture was stirred at 25 ° C. for 1 hour.
  • the peptide synthesized in Preparation Example 1 hardly permeated the membrane after 2 hours of culturing, whereas the peptide complex synthesized in Example 2 permeated the membrane. From this, it was demonstrated that the cell membrane permeability was acquired at the same time as the cyclization of the peptide by introducing the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide into the peptide.
  • RNA library containing a peptide complex having a peptide cyclized with the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide
  • NNK random base sequence
  • a template DNA (base sequence: SEQ ID NO: 1, amino acid sequence: SEQ ID NO: 2) was used to prepare this RNA library. Specifically, a reaction solution having the composition shown in Table 2-1 was used, and a 5'fragment was prepared using the plasmid as a template DNA in the PCR cycle of Table 2-2.
  • 5FragF_150409 is a forward primer (SEQ ID NO: 4)
  • Ma5frag_withoutHis_R150310 is a reverse primer (SEQ ID NO: 5).
  • A1MaNNK10_withoutHis_150531 is a forward primer (SEQ ID NO: 6) and 3FragR_150409 is a reverse primer (SEQ ID NO: 7).
  • RNA library containing 10 12 or more mRNA having the nucleotide sequence of SEQ ID NO: 3 Got As shown in FIG. 3, the mRNA contained in this library has FLAG® site, cysteine, random sequence, cysteine, TEV protease site, and spacer sequence in order from the 5'side, and has a stop codon. Absent.
  • RD complex library Preparation of ribosome display (RD) complex library>
  • the RD complex was prepared using the above RNA library using a reconstituted cell-free protein synthesis kit (“PURE flex®” manufactured by Gene Frontier).
  • This RD complex reaction solution was mixed with anti-FLAG (registered trademark) M2 antibody-bound agarose beads (manufactured by Sigma-Aldrich, 20 ⁇ L) and stirred at 4 ° C. for 60 minutes.
  • Anti-FLAG M2 antibody-bound agarose beads to which an RD complex having a FLAG sequence was selectively bound to the peptide moiety were collected.
  • the FLAG peptide was added to elute the RD complex from the agarose beads, and a ribosomal display complex library into which the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide was introduced was obtained.
  • Example 4 Preparation of RD complex containing a peptide complex having a peptide cyclized with the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide
  • RNA Preparation of RNA> Except that the random sequence in the mRNA prepared in Example 3 (in FIG. 3, the portion of "(NNK) 10 " located between the cysteine residues (C)) was used as the base sequence encoding the amino acid sequence "LYRSLPAWRYL". , MRNA was prepared in the same manner as in Example 3.
  • RD complex was prepared in the same manner as in Example 3 except that the mRNA prepared in ⁇ Preparation of RNA> was used.
  • the upper row shows the measurement results of the peptide fragment obtained when the linker molecule G3-DCX for producing a cell-penetrating cyclic peptide was not introduced, and the lower row shows the linker molecule G3- for producing a cell-penetrating cyclic peptide.
  • the measurement result of the peptide fragment obtained when DCX was introduced is shown.
  • FIG. 4 it was confirmed that a cyclic peptide (black arrow in FIG. 4) can be obtained by introducing the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide.
  • the white arrows in FIG. 4 indicate peptides that are not cyclized.
  • Example 5 Preparation of RD complex containing a peptide complex having a peptide cyclized with the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide
  • mRNA, RD complex, and linker molecule G3-DCX for producing a cell-penetrating cyclic peptide were introduced, except that the amino acid sequence “LYRSLPAWRYL” in Example 4 was changed to “PLFPWPSLWHR”.
  • a ribosome display complex was prepared. Further, in the same manner as in Example 4, a peptide fragment was obtained from the obtained RD complex, and its molecular weight was measured by MALDI-TOF MS. The results are shown in FIG.
  • the upper row shows the measurement results of the peptide fragment obtained when the linker molecule G3-DCX for producing a cell-penetrating cyclic peptide was not introduced
  • the lower row shows the linker molecule G3- for producing a cell-penetrating cyclic peptide.
  • the measurement result of the peptide fragment obtained when DCX was introduced is shown.
  • a cyclic peptide black arrow in FIG. 5
  • the white arrows in FIG. 5 indicate peptides that are not cyclized.
  • Example 6 Preparation of RD complex containing a peptide complex having a peptide cyclized with the linker molecule G3-DCX for producing a cell membrane penetrating cyclic peptide
  • the mRNA, RD complex, and linker molecule G3-DCX for producing a cell-penetrating cyclic peptide were introduced in the same manner as in Example 4, except that the amino acid sequence “LYRSLPAWRYL” in Example 4 was changed to “AGRWNVLWRTYMH”.
  • a ribosome display complex was prepared. Further, in the same manner as in Example 4, a peptide fragment was obtained from the obtained RD complex, and its molecular weight was measured by MALDI-TOF MS. The results are shown in FIG.
  • the upper row shows the measurement results of the peptide fragment obtained when the linker molecule G3-DCX for producing a cell-penetrating cyclic peptide was not introduced
  • the lower row shows the linker molecule G3- for producing a cell-penetrating cyclic peptide.
  • the measurement result of the peptide fragment obtained when DCX was introduced is shown.
  • a cyclic peptide black arrow in FIG. 6
  • the white arrows in FIG. 6 indicate peptides that are not cyclized.
  • Examples of aspects of the present invention include the following.
  • a linker molecule for producing a cell-penetrating cyclic peptide which comprises a cell membrane-penetrating cyclic peptide-imparting group and a cyclic group that cyclizes a peptide.
  • ⁇ 5> The above-mentioned ⁇ 2> to ⁇ 4>, wherein the cell membrane permeability-imparting group has a dendritic structure and the basic functional group is introduced into the end of a branch of the dendritic structure. It is a linker molecule.
  • the cyclic group is the linker molecule according to any one of ⁇ 1> to ⁇ 5>, which is an electron-withdrawing group.
  • ⁇ 7> The linker molecule according to ⁇ 6>, wherein the electron-withdrawing group has a halogen.
  • ⁇ 8> The linker molecule according to ⁇ 7>, wherein the electron-withdrawing group has two or more halogens.
  • the electron-withdrawing group is a benzyl chloride which may have a substituent.
  • the cyclization of the peptide by the cyclizing group is carried out by the reaction of the cyclizing group with at least one group selected from the group consisting of a thiol group, an amino group and a hydroxy group contained in the peptide.
  • linker molecule according to any one of ⁇ 1> to ⁇ 11>.
  • a linker molecule for producing a cell-penetrating cyclic peptide which is represented by the following structural formula.
  • ⁇ 14> A peptide complex comprising a peptide and the linker molecule according to any one of ⁇ 1> to ⁇ 13> introduced into the peptide.
  • ⁇ 15> A peptide library comprising the peptide complex according to ⁇ 14>.
  • a method for producing a peptide complex which comprises the step of introducing the linker molecule according to any one of ⁇ 1> to ⁇ 13> into the peptide.
  • ⁇ 17> The method for producing a peptide complex according to ⁇ 16>, wherein the peptide is a peptide contained in a peptide library.
  • a method for screening a functional peptide which comprises a step of screening a functional peptide using the peptide library according to ⁇ 15>.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2020/005760 2019-03-28 2020-02-14 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用 Ceased WO2020195302A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021508238A JP7611815B2 (ja) 2019-03-28 2020-02-14 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019064519 2019-03-28
JP2019-064519 2019-03-28

Publications (1)

Publication Number Publication Date
WO2020195302A1 true WO2020195302A1 (ja) 2020-10-01

Family

ID=72610871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/005760 Ceased WO2020195302A1 (ja) 2019-03-28 2020-02-14 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用

Country Status (2)

Country Link
JP (1) JP7611815B2 (https=)
WO (1) WO2020195302A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022065173A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
WO2022065172A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
CN115960162A (zh) * 2023-02-02 2023-04-14 山西医科大学 一种膜扰动抗肿瘤纳米脂肽及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011018227A2 (en) * 2009-08-12 2011-02-17 Medical Research Council Peptide libraries
WO2018089648A2 (en) * 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011018227A2 (en) * 2009-08-12 2011-02-17 Medical Research Council Peptide libraries
WO2018089648A2 (en) * 2016-11-09 2018-05-17 Ohio State Innovation Foundation Di-sulfide containing cell penetrating peptides and methods of making and using thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MOHAMMAD R JAFARI, YU HONGTAO, WICKWARE JESSICA M., LIN YU-SHAN, DERDA RATMIR: "Light-responsive bicyclic peptides", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 16, no. 41, 1 August 2018 (2018-08-01), pages 7588 - 7594, XP055743578, ISSN: 1477-0520, DOI: 10.1039/C7OB03178E *
NAILA ASSEM, DAVID J FERREIRA ,DENNIS W WOLAN ,PHILIP E DAWSON: "Acetone-linked peptides: A convergent approach for peptide macrocyclization and labeling", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 54, no. 30, 11 June 2015 (2015-06-11), pages 8665 - 8668, XP055361706, ISSN: 1433-7851, DOI: 10.1002/anie.201502607 *
PAUL R WERKHOVEN; HELMUS VAN DE LANGEMHEEN; STEFFEN VAN DER WAL; JOHN A W KRUIJTZER; ROB M J LISKAMP: "Versatile convergent synthesis of a three peptide loop containing protein mimic of whooping cough pertactin by successive Cu(I)-catalyzed azide alkyne cycloaddition on an orthogonal alkyne functionalized TAC-scaffold", JOURNAL OF PEPTIDE SCIENCE, vol. 20, no. 4, 6 April 2014 (2014-04-06), pages 235 - 239, XP055356355, ISSN: 1075-2617, DOI: 10.1002/psc.2624 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022065173A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
WO2022065172A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
CN115960162A (zh) * 2023-02-02 2023-04-14 山西医科大学 一种膜扰动抗肿瘤纳米脂肽及其制备方法和应用

Also Published As

Publication number Publication date
JP7611815B2 (ja) 2025-01-10
JPWO2020195302A1 (https=) 2020-10-01

Similar Documents

Publication Publication Date Title
EP2804872B1 (en) Norbornene modified peptides and their labelling with tetrazine compounds
JP7611815B2 (ja) 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用
JP6876002B2 (ja) 機能的要素を共有結合により係留させるための細胞透過性、細胞適合性、かつ開裂可能であるリンカー
KR20010085743A (ko) 지질 매트릭스 보조 화학결합 및 막 폴리펩티드의 합성
GB2614128A (en) Solid-phase N-terminal peptide capture and release
CA2964837C (en) Means and methods for site-specific functionalization of polypeptides
US8569452B2 (en) Preparation of phalloidin and its derivatives
CN114560846B (zh) 一种多功能化学交联剂及其制备方法和应用
CN103313724A (zh) 化合物和方法
JPWO2004009709A1 (ja) 非天然型標識化アミノ酸および該アミノ酸−ｔＲＮＡ結合体の作製方法
CN108341781A (zh) 植物次生代谢产物生物合成途径中相关酶类的解析方法
JP5306995B2 (ja) 標的物質の検出方法、並びに、これに用いるタグ、ｄｎａ、ベクター、プローブ及び検出キット
JP7763661B2 (ja) 四官能性ケミカルプローブ、及び該プローブを用いた生細胞または生組織からの標的膜タンパク質の同定方法
JP7529217B2 (ja) ペプチド複合体及びその製造方法、並びに前記ペプチド複合体の利用
CN117658991A (zh) 一种异型双功能交联剂及其制备方法与应用
WO2024043251A1 (ja) 環状ペプチドの細胞膜透過性の予測方法
CN109553596A (zh) 一种半胱氨酸荧光探针及其制备方法
EP3024823B1 (en) Intercalating amino acids
CN109312324A (zh) 核糖体展示复合体及其制造方法
CN109180620A (zh) 一种适用于半光氨酸的荧光探针及其制备方法
CN117730076A (zh) 含有四嗪部分的氨基酸
WO2022065172A1 (ja) 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
JP2023165042A (ja) 細胞膜透過性分子の細胞膜透過性の向上方法
JP2023162461A (ja) 細胞膜透過性分子の細胞膜透過性の向上方法
JP2023162460A (ja) 細胞膜透過性分子及びその利用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20779808

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021508238

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20779808

Country of ref document: EP

Kind code of ref document: A1